LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did not reach the target of A1c = 7%.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes mellitus,

• Having been treated with any other insulin, but who did not reach the target of A1c=7%.

• Ability and willingness to perform Self Monitoring Blood Glucose measurement

Exclusion Criteria:

• Will follow the prescribing information (Summary of Product Characteristics).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.